- Home
- IONS vs FRSH Comparison
IONS vs FRSH Comparison
Compare IONS & FRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- FRSH
- Stock Information
- Founded
- IONS 1989
- FRSH 2010
- Country
- IONS United States
- FRSH United States
- Employees
- IONS N/A
- FRSH N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- FRSH EDP Services
- Sector
- IONS Health Care
- FRSH Technology
- Exchange
- IONS Nasdaq
- FRSH Nasdaq
- Market Cap
- IONS 4.6B
- FRSH 3.9B
- IPO Year
- IONS 1991
- FRSH 2021
- Fundamental
- Price
- IONS $32.26
- FRSH $14.56
- Analyst Decision
- IONS Buy
- FRSH Buy
- Analyst Count
- IONS 18
- FRSH 14
- Target Price
- IONS $57.41
- FRSH $20.00
- AVG Volume (30 Days)
- IONS 1.7M
- FRSH 3.3M
- Earning Date
- IONS 04-30-2025
- FRSH 04-29-2025
- Dividend Yield
- IONS N/A
- FRSH N/A
- EPS Growth
- IONS N/A
- FRSH N/A
- EPS
- IONS N/A
- FRSH N/A
- Revenue
- IONS $717,253,000.00
- FRSH $751,550,000.00
- Revenue This Year
- IONS N/A
- FRSH $15.15
- Revenue Next Year
- IONS $27.39
- FRSH $12.72
- P/E Ratio
- IONS N/A
- FRSH N/A
- Revenue Growth
- IONS N/A
- FRSH 20.46
- 52 Week Low
- IONS $23.95
- FRSH $10.81
- 52 Week High
- IONS $52.34
- FRSH $19.77
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- FRSH 55.59
- Support Level
- IONS $31.66
- FRSH $14.04
- Resistance Level
- IONS $33.98
- FRSH $14.90
- Average True Range (ATR)
- IONS 1.30
- FRSH 0.56
- MACD
- IONS 0.41
- FRSH 0.19
- Stochastic Oscillator
- IONS 68.84
- FRSH 79.04
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About FRSH Freshworks Inc.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.